Cure­Vac jumps in­to coro­n­avirus vac­cine race; EMA backs raft of drugs, in­clud­ing No­vo Nordisk, Es­pe­ri­on com­pounds

→ You can add Cure­Vac to the list of new play­ers to jump in­to the lat­est ef­fort to con­tain a pan­dem­ic. The mR­NA com­pa­ny has joined the glob­al crew al­ready on board with the pub­lic-pri­vate Coali­tion for Epi­dem­ic Pre­pared­ness In­no­va­tions, which is adding up to $8.3 mil­lion to rapid­ly de­vel­op, man­u­fac­ture and test a new vac­cine for the coro­n­avirus 2019-nCoV. The Ger­man biotech is the lat­est biotech to see if new tech can ad­dress a scary virus that ev­i­dent­ly kills some 3% to 4% of the peo­ple who are in­fect­ed by it. Oth­ers, in­clud­ing Mod­er­na and Vir, are al­so us­ing new tech de­vel­oped over the last decade to see if they can come up with a quick way to stop the spread of the Wuhan virus, which is rat­tling pop­u­la­tions around the world.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.